January 2015

U.K. announces $21M investment in stratified medicine

Friday, January 30, 2015

Minister for Life Sciences George Freeman has announced a further $20.6 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC). Four new awards bring the total of stratified medicine consortia funded by the MRC to 13, with investments totaling over $21 million—part of the government’s $195.4 million commitment to stratified medicine set out in the U.K. life sciences strategy.

[Read More]

AstraZeneca collaborates to use CRISPR technology

Friday, January 30, 2015

AstraZeneca has announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The four research collaborations are with the Wellcome Trust Sanger Institute, Cambridge, U.K.; the Innovative Genomics Initiative, California; Thermo Fisher Scientific, Waltham, Mass.; and the Broad Institute/Whitehead Institute, Cambridge, Mass. The technology will allow AZ to identify and validate new drug targets in preclinical models that closely resemble human disease.

[Read More]

Astellas Pharma, Immunomic Therapeutics collaborate

Friday, January 30, 2015

Immunomic Therapeutics, a company developing next-generation vaccines based on the LAMP-vax platform headquartered in Hershey, Pa., and Astellas Pharma of Tokyo have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics’ vaccine designed to treat allergies induced by Japanese red cedar pollen. The companies expect to initiate a phase I trial of JRC2-LAMP-vax in Japan as soon as it is ready.

[Read More]

Amerita acquires Infusionrx

Thursday, January 29, 2015

Amerita, an Irvine, Calif.-based, wholly owned subsidiary of institutional pharmacy services company PharMerica, has completed the acquisition of Coastal Pharmaceutical Services company InfusionRx, based in Oxnard, Calif. Financial terms of the transaction have not been disclosed.

[Read More]

Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

[Read More]